Ionis Pharmaceuticals (IONS) Cash from Financing Activities (2009 - 2026)

Ionis Pharmaceuticals' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at $57.3 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 2503.82% year-over-year to $57.3 million in Q1 2026; TTM through Mar 2026 was $730.9 million, a 60.04% increase from a year earlier, with the FY2025 full-year figure at $675.8 million, up 41.37% from the prior year.
• Cash from Financing Activities slipped to $57.3 million in Q1 2026 per IONS's latest filing, from $591.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $591.2 million in Q4 2025 and bottomed at -$51.0 million in Q4 2022.
• The 5-year median for Cash from Financing Activities is $2.6 million (2024), against an average of $105.9 million.
• Biggest YoY gain for Cash from Financing Activities was 11713.83% in 2023; the steepest drop was 1859.38% in 2023.
• Year by year, Cash from Financing Activities stood at -$51.0 million in 2022, then soared by 179.82% to $40.7 million in 2023, then sank by 208.33% to -$44.1 million in 2024, then surged by 1440.05% to $591.2 million in 2025, then slumped by 90.31% to $57.3 million in 2026.
• Per Business Quant, the three latest IONS Cash from Financing Activities figures stand at $57.3 million (Q1 2026), $591.2 million (Q4 2025), and $81.2 million (Q3 2025).